Drug eluting balloon market

Drug Eluting Balloon Market, by Product Type (Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon, and Others), by End User (Hospitals, CATH Laboratories, Ambulatory Surgery Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Aug 2022
CMI2459
168 Pages
Excel & Pdf
Medical Devices

Summary

A drug-eluting balloon is a non-stent technology in which the effective homogenous delivery of anti-proliferative drugs is processed by the vessel wall through an inflated balloon.

Global drug eluting balloon market is estimated to be valued at US$ 616.6 million in 2022 and is expected to exhibit a CAGR of 8.3% during the forecast period (2022-2030).

Figure 1. Global Drug Eluting Balloon Market Share (%), by Product Type, 2022

Increasing prevalence of coronary artery disease is expected to propel growth of the drug eluting balloon market.

Increasing prevalence of coronary artery disease and diabetes is expected to propel growth of the drug eluting balloon market over the forecast period. Drug eluting balloon is an angioplasty balloon, which plays a vital role in treatment of coronary artery disease. High prevalence of coronary artery disease is expected to propel demand for angioplasty and other treatments, which in turn is expected to drive the market growth. According to the World Health Organization (WHO), in 2019 around 3.8 million men and 4.4 million women die, annually from coronary heart disease worldwide. Moreover, the number of deaths from age 15 to 59 is around 1332 Mn and for above 60 years of age is around 5825 million. Furthermore, according to the Center for Disease Control and Prevention, in July 2022, coronary heart disease is the most common type of heart disease, killing 382,820 people in 2020 globally. About 20.1 million adults age 20 and older have CAD (about 7.2%). In 2020, about 2 in 10 deaths from CAD happen in adults less than 65 years old.

Drug Eluting Balloon Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 616.6 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	8.3%	2030 Value Projection:	US$ 1,163.0 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Product Type: Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon, Others By End User: Hospitals, CATH Laboratories, Ambulatory Surgical Centers, Others
Companies covered:	Medtronic, Becton Dickinson and Company (BD), Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Koninklijke Philips N.V., Opto Circuits (India) Limited, Terumo Corporation, Surmodics, Inc., and Biotronik.
Growth Drivers:	Increasing prevalence of coronary artery disease Increasing prevalence of diabetes
Restraints & Challenges:	Adverse effects Drug Eluting Balloon such as coronary artery lesion and lumen enlargement

Figure 2. Global Drug Eluting Balloon Market Share (%), by Region, 2022

Increasing prevalence of diabetes is expected to propel growth of the drug eluting balloon market.

Diabetes can damage blood vessels and nerves associated with heart and can lead to cardiovascular disease. Therefore, increasing prevalence of diabetes is expected to propel growth of the drug eluting balloon market over the forecast period. For instance, according to WHO’s, October 2018 report, around 1.6 million deaths are registered due to diabetes globally. According to Center for Disease Control and Prevention, diabetes around the world in 2021 was 537 million adults (20-79 years) were living with diabetes - 1 in 10. China is the country with the highest number of diabetics worldwide, with around 141 million people suffering from the disease. By the year 2045, it is predicted that China would have around 174 million people with diabetes.

Furthermore, according to Center for Disease Control and Prevention, in 2019, for both men and women, prevalence of diagnosed diabetes was highest among American Indians and Alaska Natives (14.5%), followed by non-Hispanic Blacks (12.1%), people of Hispanic origin (11.8%), non-Hispanic Asians (9.5%) and non-Hispanic Whites. According to the World Health Organization, in 2019, 3.1 million adults aged 20 years or older—or 10.8% of all U.S. adults with diagnosed diabetes, started using insulin within a year of their diagnosis.

Global Drug Eluting Balloon Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, medical devices, nutrition supplements, etc. by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global drug eluting balloon market, owing to the disruption in supply chain due to COVID 19 pandemic. For instance, in July 2020, according to National Centre for Biotechnology Information, COVID-19 was disrupting distribution on a global scale. Increased border controls and customs regulations resulted in longer wait times, and lack of capacity for long-haul and last-mile fulfillment create extreme challenges. The unprecedented supply chain disruption caused by COVID-19 has had severe operational and financial consequences, with planners having to address issues including:

demand drops and surges by segment
supply shortages
inventory placement challenges and
Reduced productivity

Global Drug Eluting Balloon Market: Key Developments

In July 2021, Medtronic plc., a medical device company, launched the Prevail drug coated balloon (DCB) Catheter in Europe following CE (Conformité Européene) mark. The coronary DCB in market, the Prevail DCB is used during percutaneous coronary intervention (PCI) procedures to treat narrowed or blocked coronary arteries in patients with coronary artery disease (CAD). During the catheter-based procedure, the balloon inflates within the artery, while the drug is delivered to the arterial tissue where it is absorbed. The Prevail DCB utilizes a rapid absorption drug – paclitaxel – to enable treatment of de novo lesions, small vessel disease, and in-stent restenosis (ISR). DCB angioplasty does not require a permanent implant and is often used in cases where the implantation of a drug-eluting stent (DES) is not desirable or is technically challenging.

Global Drug Eluting Balloon Market: Restraint

The major factors that hinder growth of the global drug eluting balloon market include adverse effects Drug Eluting Balloon such as coronary artery lesion and lumen enlargement. For instance, in May 2017, Abbott recalled three balloon catheters due to difficulty in removing balloon sheath, which caused 19 reports of injury and 1 death.

Key Players

Major players operating in the global drug eluting balloon market include Medtronic, Becton, Dickinson and Company (BD), Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Koninklijke Philips N.V., Opto Circuits (India) Limited, Terumo Corporation, Surmodics, Inc., and Biotronik.

Table of Content

Table of Contents

*Browse 35 market data tables and 28 figures on "Global Drug Eluting Balloon Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global drug eluting balloon market during the forecast period (2022-2030)?

The global drug eluting balloon market size is estimated to be valued at US$ 616.6 million in 2022 and is expected to exhibit a CAGR of 8.3% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increasing prevalence of coronary artery disease and increasing prevalence of diabetes are expected to drive the market growth.

Which is the leading product type segment in the market?

Peripheral Drug Eluting Balloon is the leading product type segment in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include adverse effects Drug Eluting Balloon such as coronary artery lesion and lumen enlargement.

Which are the major players operating in the market?

Major players operating in the market include Medtronic, Becton, Dickinson and Company (BD), Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Koninklijke Philips N.V., Opto Circuits (India) Limited, Terumo Corporation, Surmodics, Inc., and Biotronik.